Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma.


Journal

Revista espanola de enfermedades digestivas
ISSN: 1130-0108
Titre abrégé: Rev Esp Enferm Dig
Pays: Spain
ID NLM: 9007566

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 23 3 2022
medline: 20 4 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.

Identifiants

pubmed: 35315679
doi: 10.17235/reed.2022.8775/2022
doi:

Substances chimiques

Yttrium Radioisotopes 0
Yttrium-90 1K8M7UR6O1

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-197

Auteurs

Marta Burrel (M)

Radiología. Sección Angiorradiología, Hospital Clínic de Barcelona.

Patricia Bermúdez (P)

Radiología. Sección Angiorradiología, Hospital Clínic de Barcelona.

Alejandro Forner González (A)

Liver Unit, Hospital Clínic de Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH